NIKKEI 225
27,777.90 -448.18 (-1.59%) HANG SENG
18,714.14 -22.30 (-0.12%) CRUDE OIL
81.35 +0.13 (+0.16%) GOLD FUTURES
1,816.20 +1.00 (+0.06%) DOW
34,395.01 -194.76 (-0.56%) BTC-GBP
13,829.90 -176.63 (-1.26%)
Amgen Inc. (AMGN)
After hours:
| Previous close | 286.40 |
| Open | 288.00 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 800 |
| Day's range | 279.91 - 288.09 |
| 52-week range | 200.84 - 296.67 |
| Volume | |
| Avg. volume | 2,833,263 |
| Market cap | 161.06B |
| Beta (5Y monthly) | 0.58 |
| PE ratio (TTM) | 23.68 |
| EPS (TTM) | 12.07 |
| Earnings date | 06 Feb 2023 - 10 Feb 2023 |
| Forward dividend & yield | 7.76 (2.98%) |
| Ex-dividend date | 17 Aug 2022 |
| 1y target est | 254.85 |
- Bloomberg
Horizon Therapeutics in Separate Sale Talks With Amgen, Sanofi, J&J
(Bloomberg) -- Horizon Therapeutics Plc rose by the most in more than three years after the drug developer disclosed it’s in talks with a trio of potential suitors about a possible sale of the company.Most Read from BloombergScientists Revive 48,500-Year-Old ‘Zombie Virus’ Buried in IceAn Arizona County’s Refusal to Certify Election Results Could Cost GOP a House SeatStock Traders Cheer Powell’s Risk-Friendly Shift: Markets WrapNYC Becomes One Billionaire Family’s Haven From China Property Crash
- Motley Fool
Why Horizon Therapeutics Stock Is Skyrocketing Today
Shares of Horizon Therapeutics (NASDAQ: HZNP) were skyrocketing 27.2% higher as of 10:48 a.m. ET on Wednesday. The big jump came after the company announced Thursday evening that it's in discussions with Amgen (NASDAQ: AMGN), Johnson & Johnson (NYSE: JNJ) subsidiary Janssen, and Sanofi (NASDAQ: SNY) about potentially being acquired. There were two words in Horizon's press release that investors should note: "highly preliminary."
- Reuters
J&J sues Amgen over plan to sell drug similar to blockbuster Stelara
(Reuters) -Johnson & Johnson's Janssen unit has sued Amgen Inc over its plan to market a drug for ulcerative colitis and other conditions similar to J&J's top-selling Stelara, saying it would infringe two patents in a lawsuit made public on Wednesday. Stelara accounted for $9.1 billion of J&J's $52 billion in global drug sales last year. It is a biologic drug, meaning it is made inside living cells.
